2,425,010 Shares in Zoetis Inc. $ZTS Bought by Ruane Cunniff & Goldfarb L.P.

Ruane Cunniff & Goldfarb L.P. acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,425,010 shares of the company’s stock, valued at approximately $286,660,000. Zoetis comprises about 4.8% of Ruane Cunniff & Goldfarb L.P.’s investment portfolio, making the stock its 10th largest position.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. J. Stern & Co. LLP lifted its holdings in shares of Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after buying an additional 23,877,416 shares during the last quarter. State Street Corp lifted its holdings in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after buying an additional 149,382 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after buying an additional 189,235 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Zoetis in the 4th quarter valued at approximately $734,425,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 2.1%

Shares of NYSE:ZTS opened at $76.91 on Tuesday. The company has a market cap of $32.24 billion, a P/E ratio of 12.75, a P/E/G ratio of 1.18 and a beta of 0.75. The stock’s 50-day moving average is $77.27 and its 200-day moving average is $103.71. Zoetis Inc. has a 52-week low of $71.47 and a 52-week high of $160.48. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the previous year, the firm posted $1.48 earnings per share. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts predict that Zoetis Inc. will post 6.87 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.

Insider Transactions at Zoetis

In related news, Director Paul Bisaro acquired 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Frank A. Damelio acquired 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 11,650 shares of company stock worth $886,384 over the last three months. 0.22% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Barclays dropped their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Stifel Nicolaus decreased their target price on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research report on Friday, June 26th. Citigroup dropped their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. TD Cowen cut their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Finally, Morgan Stanley reduced their price objective on shares of Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a research note on Wednesday, July 22nd. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Zoetis has a consensus rating of “Hold” and a consensus target price of $118.33.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.